# US 2026/0152572 A1 · Novel anti-pad2 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0152572 A1
- Document ID: US20260152572A1
- Status: Published application
- Kind: A1
- Application number: 19/456,545
- Filed: 2026-01-22
- Published: 2026-06-04
- Earliest claimed: 2018-06-20
- Assignees: Pharma Foods International Co., Ltd.
- Applicants: Pharma Foods International Co., Ltd.
- Inventors: Kenji SAITO; Tomoko SAKATA; Takaaki KAWANOBE; Keita KOGA
- Web page: https://patentgrep.com/patent/US20260152572A1

## CPC

- C07K 16/40: against enzymes
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12Y 305/03006: Arginine deiminase (3.5.3.6)
- C07K 2317/23: from birds
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12Y 305/03015: Protein-arginine deiminase (3.5.3.15)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

To obtain an anti-PAD2 antibody having excellent PAD2 inhibitory activity. Provided is an anti-PAD2 antibody that specifically binds to positions 341 to 357 of PAD2. Also provided is an anti-PAD2 antibody that specifically binds to a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 1.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method for treating rheumatoid arthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-PAD2 antibody, wherein the anti-PAD2 antibody specifically binds to a calcium-bound human PAD2 and inhibits citrullination activity of the calcium-bound human PAD2, and wherein a KD (M) of the anti-PAD2 antibody toward human PAD2 is 9.0×10−8 or less.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the anti-PAD2 antibody inhibits citrullination of a histone.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the anti-PAD2 antibody inhibits citrullination of a myelin basic protein.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the anti-PAD2 antibody is a monoclonal antibody.

### Claim 21 (depends on 17)

The method according to claim 17, wherein the anti-PAD2 antibody is a recombinant antibody.

### Claim 22 (depends on 17)

The method according to claim 17, wherein the subject suffers from rheumatoid arthritis.

### Claim 23 (depends on 18)

The method according to claim 18, wherein the anti-PAD2 antibody is a monoclonal antibody.

### Claim 24 (depends on 18)

The method according to claim 18, wherein the anti-PAD2 antibody is a recombinant antibody.

### Claim 25 (depends on 18)

The method according to claim 18, wherein the subject suffers from rheumatoid arthritis.

### Claim 26 (depends on 19)

The method according to claim 19, wherein the anti-PAD2 antibody is a monoclonal antibody.

### Claim 27 (depends on 19)

The method according to claim 19, wherein the anti-PAD2 antibody is a recombinant antibody.

### Claim 28 (depends on 19)

The method according to claim 19, wherein the subject suffers from rheumatoid arthritis.
